These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17660491)

  • 41. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
    Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
    Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
    Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
    Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
    Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
    Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
    Kullmann F; Hollerbach S; Dollinger MM; Harder J; Fuchs M; Messmann H; Trojan J; Gäbele E; Hinke A; Hollerbach C; Endlicher E
    Br J Cancer; 2009 Apr; 100(7):1032-6. PubMed ID: 19293797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
    Petrelli F; Inno A; Ghidini A; Rimassa L; Tomasello G; Labianca R; Barni S;
    Eur J Cancer; 2017 Aug; 81():174-182. PubMed ID: 28633088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
    Merchan JR; Ferrell A; Macintyre J; Ciombor KK; Levi J; Ribeiro A; Sleeman D; Flores A; Lopes G; Rocha-Lima CM
    Am J Clin Oncol; 2012 Oct; 35(5):446-50. PubMed ID: 21552097
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
    Lee KH; Kim MK; Kim YH; Ryoo BY; Lim HY; Song HS; Kim HK; Lee MA; Im SA; Chang HM; Cho JY; Zang DY; Kim BS; Kim JS
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):317-25. PubMed ID: 19034448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Gemcitabine-based combinations in inoperable pancreatic cancers].
    Louvet C; André T; Artru P
    Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
    Scheithauer W; Van Cutsem E
    Colorectal Dis; 2003 Nov; 5 Suppl 3():36-44. PubMed ID: 23573559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
    Zheng T; Jin J; Zhou L; Zhang Y
    Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
    Kulke MH
    Lancet Oncol; 2005 Jun; 6(6):352-3. PubMed ID: 15948320
    [No Abstract]   [Full Text] [Related]  

  • 60. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
    Oettle H; Riess H; Stieler JM; Heil G; Schwaner I; Seraphin J; Görner M; Mölle M; Greten TF; Lakner V; Bischoff S; Sinn M; Dörken B; Pelzer U
    J Clin Oncol; 2014 Aug; 32(23):2423-9. PubMed ID: 24982456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.